Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

SHA:688266 Revenue

Suzhou Zelgen Biopharmaceuticals had revenue of 299.99M CNY in the quarter ending June 30, 2026, with 44.22% growth. This brings the company's total for the last twelve months to 1.64B, up 145.57% year-over-year. In the year 2025, Suzhou Zelgen Biopharmaceuticals had annual revenue of 810.48M with 52.07% growth. That makes Suzhou Zelgen Biopharmaceuticals the 15,949th largest company in the world by revenue and 2,870th in China.

• Revenue (ttm): 1.64B
• Revenue Growth: +145.57%
• P/S Ratio: 16.06
• Revenue / Employee: 1.55M
• Employees: 1,055
• Market Cap: 26.08B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• China 802.64M 99.1%
• Overseas 7.55M 0.9%

Fiscal year ended Dec 31, 2025 See the full SHA:688266 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	810.48M	277.53M	52.07%
Dec 31, 2024	532.95M	146.52M	37.91%
Dec 31, 2023	386.44M	84.13M	27.83%
Dec 31, 2022	302.31M	111.94M	58.81%
Dec 31, 2021	190.36M	162.70M	588.19%

Data Source: S&P Global Market Intelligence Last updated: Jul 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error